AM-2233
外觀
![]() | |
法律規範狀態 | |
---|---|
法律規範 |
|
識別資訊 | |
| |
CAS號 | 444912-75-8 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.233.382 |
化學資訊 | |
化學式 | C22H23IN2O |
摩爾質量 | 458.34 g·mol−1 |
3D模型(JSmol) | |
| |
|
AM-2233,化學名:1-[(N-甲基-2-哌啶基)甲基]-3-(2-碘苯甲酰基)吲哚,分子式C22H23IN2O,屬於亞歷山德羅斯·馬克里揚尼斯小組合成的苯甲酰基吲哚類AM系列大麻素[1][2],2015年列入《非藥用類麻醉藥品和精神藥品名錄》[3]。
參考文獻
[編輯]- ^ Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, et al. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. Journal of Medicinal Chemistry. October 2005, 48 (20): 6386–6392. PMID 16190764. doi:10.1021/jm050135l.
- ^ Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, et al. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chemistry & Biology. November 2008, 15 (11): 1207–1219. PMC 3700404
. PMID 19022181. doi:10.1016/j.chembiol.2008.10.011.
- ^ 关于印发《非药用类麻醉药品和精神药品列管办法》的通知. China Food and Drug Administration. 27 September 2015 [1 October 2015]. (原始內容存檔於1 October 2015) (中文).